Kidney transplant study tests safer rejection prevention
NCT ID NCT02377193
First seen Jan 04, 2026 · Last updated Jun 17, 2026 · Updated 29 times
Summary
This study tested two different drugs (Simulect and ATG) given at the time of kidney transplant to prevent organ rejection in patients with a high risk of rejection. Sixty sensitized patients (those with antibodies against many potential donors) were enrolled. The goal was to see which drug better prevents treatment failure, including rejection, graft loss, or death, within 6 months after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UHToulouse
Toulouse, France, 31059, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.